Abstract Both metabolomic and genomic approaches are valuable for risk analysis, however typical approaches evaluating differences in means do not model the changes well. Gene polymorphisms that alter function would appear as distinct populations, or metabotypes, from the predominant one, in which case risk is revealed as changed mixing proportions between control and case samples.
Introduction
Improving risk prediction is increasingly important for early intervention and prevention. Several well known risk prediction algorithms are employed-such as the Prospective Cardiovascular Munster (PROCAM) study (Assmann et al. 2002) , the 3rd Joint European Task Force [Systematic Coronary Risk Evaluation (SCORE)] (De Backer et al. 2004) , the Atherosclerosis Risk in Communities (ARIC) study (Chambless et al. 2003) , the Reynolds Risk Score (Ridker et al. 2007 (Ridker et al. , 2008 and finally, the original and most widely used system, the Framingham Risk Score (D'Agostino et al. 2008; Wilson et al. 1998) . The last was designed to predict the 10-year risk for major coronary events, and it does so with a c-statistic [area under the receiver operating characteristic (ROC) curve] of 0.7-0.8 (Chambless et al. 2003; D'Agostino et al. 2008; Wilson et al. 1998 ). All of these prediction algorithms generally include the following standard risk factors: age, sex, total (or low-density lipoprotein) cholesterol (C), high-density lipoprotein C (HDL-C), blood pressure, and both smoking and diabetes status. Despite the utility of standard factors in coronary heart disease (CHD) risk estimation, there remains an intense interest in finding additional markers that would improve upon this standard (Cook 2007 (Cook , 2008 Vasan 2006) ; however, while a number of putative risk factors have been tested, few have added meaningfully (Folsom et al. 2006; Lloyd-Jones et al. 2006) . Surprisingly, a relationship between leading gene variants related to classical risk markers for acute coronary syndrome was not validated in the data used here (Morgan et al. 2007) , demonstrating the challenges in this endeavor. To date such analyses have rarely considered fatty acid metabolism, however we have demonstrated that models based on the erythrocyte fatty-acid profiles can outperform classic risk models in case/control discrimination (Shearer et al. 2009 ).
Here we considered how we could employ an approach that jointly emphasizes the impact of genetic variance on metabolomic datasets.
A typical approach to comparison of phenotypes across case/control populations is to compare the component means using methods like the two-sample t test (with or without pooled variance) and generalizations of these approaches in a regression framework. In case/control settings this translates into testing for evidence of a shift in the means between the two components, with the hypothesis that d = 0, where l Case = l Control ? d (illustrated in Fig. 1a ). However considering the metabolic mechanisms that give rise to the relative abundances of fatty acids-e.g. genes, diet, and lifestyle patterns-testing for a difference in means may not be optimal, since what appears to be a shift in means could actually be a shift in the relative abundance of distinct metabotypes, or metabolic phenotypes, in the study case versus control populations. While the term is most commonly applied to arrays comprising multiple metabolites that together represent a ''readout of the metabolic state'' (Holmes et al. 2008 ), here we consider the concept of a metabotype as a phenotypic variation within a single biomarker of enzymatic behavior, or activity. Thus, functionally distinct genotypes should give rise to distinct metabotypes in large population samples. For example, delta-9 desaturase (D9D) catalyzes desaturation of 16-carbon and 18-carbon fatty acids. It is critical in the synthesis of palmitoleic and oleic acids from palmitic and stearic acids respectively. In vivo, this activity can be estimated by the palmitoleic to palmitic acid or the oleic acid: stearic acid ratio (SA) as OA:SA (Vessby et al. 2002) . In a population with two D9D genotypes, having unique activities (k m , b max ), each genotype would define a unique OA:SA mean with variance around the mean determined by diet, lifestyle and other environmental factors. Figure 1b shows how two D9D populations with unique means (l) and variance (r 2 ) would appear in a population sample.
In this case, a simple comparison of the means is likely to ignore the underlying biological cause: that the observed (marginal) distribution of fatty-acid levels in the case and control samples, respectively, represent a mixture of two or more underlying distributions, or components, derived from each genetically determined metabotype.
In this paper we propose a likelihood ratio test (LRT) method for testing case/control metabotype differences. The test estimates the metabotype mean of each sample, and then tests for differences in the relative frequencies of the metabotypes in the case/control samples. We compare the proposed LRT method to means testing on the marginal distributions of FA levels and a Chi squared (v 2 ) test using the estimated metabotype frequencies and find that the LRT is most powerful across a wide variety of situations. We then apply our methodology to the previously analyzed case/control study of 767 ACS-cases and their matched controls (Shearer et al. 2009 ) to determine whether multiple populations of FA elongase and destaturases can be identified and if so whether the relative abundance of these populations differ between cases and controls. Numerous differences in cases and controls metabotype frequencies are identified and the resulting insights enhance biological interpretability.
Methods

Summary of approach
We first validated the proposed test using simulated data, then applied it to an established fatty acid dataset where conclusions regarding risk for ACS could be drawn. In validating the novel statistical approach (LRT), two objectives were considered: (1) demonstrating that the test yields an accurate type I (a; false positive) error rate; and (2) that when an effect is present, the test finds the effect (1-b (power); true positive). Since the proposed test more plausibly conforms to biological mechanisms than the current standard, our primary endpoint was to demonstrate power equivalent to current approaches. As a secondary endpoint, we sought to demonstrate that the test outperforms current approaches in some situations.
In applying the test to real world data, we used a fatty acid dataset where prior knowledge of its usefulness existed (Shearer et al. 2009 ). Here, the LRT test was used to answer two questions: (1) do multiple components, referred to here as metabotypes, exist in the sampled populations; and (2) is there a difference between the mixing proportions in the control and ACS populations; or more simply: does one metabotype appear to confer risk for ACS by virtue of greater prevalence among ACS subjects. Although many factors might explain why there are multiple metabotypes in a sample population, consideration of how genetics-induced differences in enzymatic function might appear in a lipidomic analysis of large cohorts guided our development of this approach. Thus we also utilized genetic models of inheritance (dominant, recessive and additive where appropriate to determine whether the observations of metabotypes conformed to it.
Ethical statements and compliance
This research was performed in accordance with the ethical principles for medical research involving human subjects outlined in the Declaration of Helsinki. The study was approved by the Institutional Review Board of Saint Luke's Hospital and the Institutional Review Board of the University of Missouri-Kansas City School of Medicine.
Subject selection
Patients diagnosed with an ACS were recruited as previously described. A total of 1661 patients were enrolled and samples obtained. Control subjects having routine blood draws were recruited as described from the same location as [80 % of the cases.
Laboratory methods
RBC-FA composition was measured as previously described (Block et al. 2007 ) using the boron trifluoride methylation method and followed by gas chromatography (GC) analysis using an Agilent 6890 (Agilent Technologies, Palo Alto, CA) equipped with a capillary column (SP2560, 100 m., Supelco, Bellefonte, PA). The solid black population is centered at 1.23 and the dashed grey population is centered at 1.30. In this context comparison of means are made using F-distributions to determine the probability that they are the same. Binned data corresponding to a biomarker for desaturation of stearic acid to oleic acid, or D9D activity, are shown by data points, and skewed from normality. In b, the distribution of the control (a, solid black) data is fit to two gaussian distributions (bold black line). Two phenotypes of D9D activity exist here, the first (dark grey), representing less efficient D6D activity at 1.17 ± 0.25 and the second (lighter grey) representing efficient activity at 1.96 ± 0.25. Using component mixture modeling, the distributions of each metabotype, or metabolic phenotype, have been deconvoluted from the parent distribution. In c, the deconvolution can be used to test whether the apparent abundance of the efficient D9D phenoptype occurs more frequently among the cases (as it apparently does) and whether the less efficient phenotype occurs with greater frequency among the controls Mixture modeling identifies optimal metabolism 1329 2.5 Activity biomarkers
We used product:precursor ratios in pathways of human fatty acid metabolism to obtain estimates of bioactivity (Supplemental Fig. 1) . A summary of each activity biomarker is listed in supplementary Fig. 1b . Since our intention was to develop an analytical approach combining both genetic and metabolomic considerations, we reference the activity estimates by the predominant human gene responsible for the activity however as noted, there could be other explanations for the presence of multiple components.
Test validation via simulation
To evaluate the performance of different statistical tests for case/control differences in FA levels, we conducted two main simulation studies: (1) data simulated from a two component mixture model; (2) data simulated from a three component mixture model. In the simulation analysis involving a two-component mixture model we simulated two normal distributions, with a one unit difference in means between the two components. We considered standard deviations in the first group of either s 1 = 0.25 or 0.50, and standard deviations in the second component (s 2 ) either the same, 50 % larger or 100 % larger than the first component. We simulated 800 cases and 800 controls from the two component normal mixture distribution, where the mixing proportions (p 1 and p 2 ) may be the same (no association between genotype and disease) or different (association between genotype and disease) in the cases and controls. The proportion of controls in component 1 was simulated to follow either a dominant or recessive genetic mode of inheritance. In particular, we considered risk (minor) allele frequencies of f = 5, 10, 25, 33 and 50 %. Under an assumption of Hardy-Weinberg Equilibrium, this yields the following proportions of controls in component 2 (p 2,controls ; Dominant: 9.75, 19, 43.75, 55.1 and 75 %; Recessive: 0.25, 1, 6.25, 10.9 and 25 %, where these proportions are computed as p 2,controls,dominant = f 2 ? 2f(1 -f) and p 2,controls,recessive = f 2 . The proportion of cases in component 1, p 1,cases was set to either be the same, 90, 75 or 50 % the size of p 1,controls , representing a risk allele with varying amounts of impact on disease risk. Thus, there were a total of 240 simulation settings (2 (s 1 ) 9 3 (s 2 ) 9 10 (p 2,controls ) 9 4 (p 2,cases ) considering a two-component normal distribution. Five-hundred randomly generated sets of data were created for each simulation setting. Empirical type I error and power were both computed as the proportion of the 500 data sets for which the p-value was less than 0.05.
We also simulated data from a three component normal mixture model. We considered the following settings. All simulation settings used a 1-unit difference between each of the three means of the components. The standard deviation for the first component was either 0.25 or 0.50, while the standard deviations of the remaining components were either the same, or different (50 % larger in second, 100 % larger in third). We simulated 800 cases and 800 controls. Similar to the two-component mixture simulation, we considered risk (minor) allele frequencies of f = 5, 10, 25, 33 and 50 %. The size of the three components in the controls was again determined using Hardy-Weinberg equilibrium. Case proportions in components one, two and three were computed to represent an additive, increasing risk model. In particular, Xg 1 ,(1 -X)g 1 ?Xg 2 , (1 -X)g 2 ?g 3 , are the three case component proportions respectively, where X = 1, 0.9, 0.75 or 0.5, and g 1 , g 2 and g 3 represent the component proportions in the controls. Thus, there were a total of 80 simulation settings (2 (s 1 ) 9 2 (s 2 ) 9 5 (p 2,controls ) 9 4 (p 2,cases ) using a threecomponent normal distribution.
Methods of analyzing metabotype data
When analyzing simulated and real data, we used a variety of methods of analyzing fatty acid levels. To aid in the understanding of these approaches we begin by introducing some notation. Let G i represent a random variable indicating the observed fatty acid level when an individual is truly in the ith metabotype. We assume that G i $ N l i ; r i ð Þ, where l i ; r i indicate the mean and standard deviation of the normally distributed fatty acid levels within the ith metabotype. Then, X $ P k i¼1 p x;i G i , where X represents the observed distribution of fatty levels within the case population, and p x;i is the proportion of cases with the ith metabotype, where
Standard methods of evaluating differences in X and Y include the t test, which uses t ¼ xÀy s x;y , where x; y are the sample means of the cases and controls, and s x;y , is a function of the sample standard deviations (s x , s y ) and sample sizes (n x , n y ) in the case and control samples, respectively, and can be estimated using assumptions of equal or unequal variance. A common non-parametric alternative is the Mann-Whitney test, which first computes the ranks, r j , of the n x ? n y combined sample of fatty acid levels, and then evaluates the difference between the average rank of the case and control samples (r x ; r y and the expected average rank if the samples were from the same population.
We consider two methods here which reflect the underlying assumption of observed samples which are mixtures of different metabotypes. The first method using metabotypes is a v 2 test of independence can be used on the resulting 2 9 k table of categorized individuals which occurs from cross-classifying individuals by disease status and estimated metabotype. Metabotypes were estimated by using MClust (Fraley 2012 ) to fit a 2 or 3 component mixture distributions using an expectation-maximization algorithm. For a given mixture model, each individual can be assigned a vector of posterior probabilities corresponding to the individuals likelihood of belonging to each component of the mixture distribution (see details in the following section). An individual can then be classified to the ''most likely'' metabotype by using the maximum posterior probability. The second method (Kim et al. 2008) does not require the use of maximum posterior probabilities to classify individuals into metabotypes. Instead, Kim et al. use a likelihood ratio test (LRT) to compare the full distribution of posterior metabotype probabilities between cases and controls. Two different versions of the LRT were considered: (1) one where the number of distinct metabotypes (k) was considered known a priori (LRT k ); (2) one where the number of distinct metabotypes (k) was estimated from the data (LRT est ).
Statistical analysis of simulated data
Data was simulated as described earlier using R version 3.0.3. Each of the different methods of analyzing fatty acid data (see Sect. 2.7) was then applied to the data yielding a p value measuring the strength of evidence of a difference in the means, distributions, or mixing proportions of metabotypes between cases and controls, depending on the test used. Type I error rates and power were estimated by dividing the number of simulations yielding a p-value less than 0.05 by the total number of simulations at that setting. For the LRT test, a single component represents a case where no difference exists.
Statistical analysis of real data
We used a multi-step procedure to analyze the real fatty acid data. First, we used Mclust (Fraley 2012) to fit 1, 2 or 3 component mixtures of equal variance normal distributions to each of the 14 fatty acid ratios, for a total of three different models being estimated on each fatty acid ratio. The model yielding the largest Bayesian Information Criterion (BIC) was deemed the best fitting model for the FA. The guidelines of Raftery (Raftery 1995) were used to ensure the best fitting model was significantly better than other models, namely, that the improvement in BIC is at least 6 when comparing the best to second best fitting model. We also fit models after dropping the most extreme 0.5 % of the FA values (top 0.25 and bottom 0.25 %), since this class of model fitting techniques can be sensitive to extreme values (Mendell et al. 1993) .
We then applied the LRT (see Sect. 2.7 for details) to each data using the estimated number of components. The R-code is posted on the first author's software page (http:// www.dordt.edu/academics/programs/math/statgen/software. shtml). All other tests described above were also applied to the data. Odds ratios were estimated using a logistic regression model predicting case/control status by each individual's metabotype posterior probability for a particular fatty acid. Recent related results have illustrated the near optimality (vs. LRT) of using posterior probabilities to predict case/control status in such models (Liu et al. 2013a) . Two sided tests at significance level 5 % were used in all cases. Missing FA data was below 0.8 % (range 0-0.8 %) for all 9 of the FA ratios.
Results
Two component simulations
The type I error rate (false positives) for the proposed LRT test was well controlled (Supplemental Table 1 ), and this was the case whether we affirmed prior knowledge of two metabotypes (LRT 2 ) or if the number of metabotypes was unknown and the test was required to estimate the metabotype number (LRT est ). The type I error rate was comparable and well-controlled by all methods (equal and unequal variance t tests, Mann-Whitney test, v 2 test, LRT 2 and LRT est ) across all simulation settings considered here. In particular, in almost all cases, a 95 % CI on the empirical type I error rate contains the nominal type I error rate of 5 %. Minor exceptions occurred when the sample size of one component was small, yielding slightly conservative or slightly liberal type I error rates for methods estimating metabotype proportions from the data (v 2 test, LRT 2 and LRT est ).
In addition to control of type 1 errors, both LRT methods provided superior power in most scenarios. Supplemental Table 2 illustrates the power of case/control association tests when there is a difference between component proportions in cases and controls. Ninety-two of 180 simulation settings yielded power greater than 99 % for all six methods considered here, meaning model selection is not particularly important in such contexts. In 70 out of the remaining 88 settings, the LRT 2 yields power equivalent to or better than the equal variance t test, the unequal variance t test, the Mann-Whitney test and the v 2 test. On average, LRT 2 provided an increase in power of 4 % points compared to both the equal and unequal variance t tests (min = 0, max 15 point increase), 12.5 percentage points more power than the Mann-Whitney test (min = 0, max = 44.4 point increase) and 3.9 % points more power than the v 2 test (min = 0, max = 15.4 % points). In the 18 settings when the LRT 2 was not the most powerful test, the equal and unequal variance t tests were on average 0.7 % points better (min = -1 point, max = 2.4 points), the Mann-Whitney test was, on average, 2.6 points better (min = -0.8 points, max = 8.8 points) and the v 2 test was, on average, 8.2 points better (min = 0, max = 21.6 points). LRT 2 tended to be best when the standard deviations were smaller and equal and when differences in the case/control proportions were smaller.
In 59 out of the 88 settings LRT est yielded power equivalent to or better than the equal variance t test, the unequal variance t test, the Mann-Whitney test and the v 2 test. On average across the 59 settings, LRT est provided 4 percentage points more power than both the equal and unequal variance t tests (min = 0, max = 15 points), 13.9 points better than the Mann-Whitney test (min = 0.2 points, max = 44.4 points) and 4 points better than the v 2 test (min = 0, max = 15.4 points). In the remaining 29 settings the average amount that both t tests were better than LRT est was 1.1 points (min = -2.4 points, max = 6.4 points), for Mann-Whitney the average improvement was 2.2 points (min = -1.8 points, max = 8.6 points) and for the v 2 test the average improvement was 4 points (min = -15.8 points, max = 5.6 points). LRT est tended to be optimal in the same situations as LRT 2 . Figure 2 illustrates simulation setting where 90.25 % of controls are in component 1 and 81.2 % of cases are in component 1. The standard deviation is the same in both components and varies on the x-axis; the difference in component means is fixed at 1. The figure illustrates that the LRT est is more powerful than all other tests in this case.
Three component simulations
The type I error rate for the v 2 test, the LRT 3 , and the LRT est was well controlled for settings with three components (Supplemental Table 3 ) as long as the sample size in each of the three components was reasonably large (at least three observations). The t tests and Mann-Whitney tests showed type I error control in all situations. Twenty-one of 60 settings yielded power greater than 99 % for all six methods considered here, meaning model selection is not particularly important in such contexts. In 11 of the remaining 39 settings the LRT 3 is the most powerful, with average power gain versus the t test of 0.3 points (min = 0, max = 1.6 points), versus the Mann-Whitney test of 2.6 points (min = 0, max = 15.4 points) and versus the v 2 test of 46.4 points (min = 0, max = 100 points), however we note that the v 2 test often suffers from small sample size issues in this simulation, yielding low power. In 24 of the 39 settings LRT est was the most powerful of all methods with an average improvement versus the t test of 1 point (min = 0, max = 7 points), versus Mann-Whitney 5.7 points (min = 0, max = 26.8 points) and 56.7 points versus v 2 (min = 1.2 points, max = 100 points). In general, across the settings we investigated it was much harder to correctly identify the data as being produced from a threecomponent mixture model, than a two component mixture. We note that in many cases the best model was a two component model because of the small number of individuals present in the third component. As sample size increases the performance of the three component mixture model and test improves (details not shown). In general, the LRT test performs better than other tests in similar ways to those described earlier.
Case and control plasma fatty acids
The means and standard deviations overall, and within each of the case/control samples for each of the fourteen fatty acid ratios considered here are provided in Supplemental Table 5 . Correlation between fatty acid ratios are provided in Supplemental Table 6 . Notably, correlations within closely related pathways are stronger than among distantly related ones.
Metabotypes estimations
We defined metabotypes to be single components of each mixture, and each component could be comprised of case or control subjects. We used MClust to fit 1, 2 and 3 component mixtures of normal distributions for each of the activity surrogates (i.e. fatty acid ratios). Most fatty acids had a clear ''best fitting model'' that was robust to the potential presence of outliers. Of the 14 activity biomarkers explored, eleven were clearly mixtures of two components. One activity, ELOVL2, was ambiguously either not different or a mixture of three components (see Supplemental  Tables 7a, b for details), and no further analysis was conducted.
3.5 Case/control metabotype differences
We next tested whether the proportion of metabotypes differed among cases and controls. Table 1 gives the estimated means and standard deviations of each component for the 11 activity biomarkers for which a 2-component normal mixture model fit best. Among enzymes acting on saturated and mono-unsaturated fatty acids, two differences were notable: D9D activity and ELOVL6 activity. For D9D activity on 16-and 18-carbon fatty acids, two metabotypes were present: a more common low activity metabotype, and a metabotype with a higher mean activity. While this high activity metabotype was less common, the higher 18:1n9/18:0 ratio was more abundant in cases (14.8 %) than controls (7.1 %) (p unadjusted \ 0.0001). Adjusting for other fatty acids in the pathway nullified the difference however a reduced risk, Odds Ratio (OR) = 0.3 (0.2, 0.6; p adjusted \ 0.0001), persisted for subjects with higher 18:1n9/18:0 based activity than on the 16:1n7/16:0-based activity. Two metabotypes were also observed among ELOVL6 populations. While only 40 % of control subjects had the lower activity metabotype, nearly 50 % of cases did (p \ 0.0001) suggesting lower elongation activity is associated with a higher risk. Similarly, key difference among cases and controls were observed among biomarkers of enzymes acting on polyunsaturated fatty acids. Three differences were noted: ELOVL5 activity on omega-6 fatty acids, Sprecher pathway chain shortening activity, and FADS1 activity; the lattermost only apparent after adjustment. For ELVOL5, only 7 % of controls had the high activity metabotype compared to 20 % of cases (p adjusted \ 0.0001), indicating metabotypes having increased elongation of gLA to dgLA can confer risk. The production of 22-carbon fatty acids (n6-DPA and DHA) is a multi-step process sometimes termed Sprecher-pathway chain shortening (SCS). It comprises elongase and peroxisomal beta-oxidation activities, (Supplemental Fig. 1b) (Ferdinandusse et al. 2001; Sprecher 2000) . Subjects with high SCS activity on omega-3 fatty acids represented 10 % of the controls, however they represented only 4.5 % of the cases. Adjustment for other fatty acids ablated this effect, however the effect persisted when the relative SCS activity on omega-3 to omega-6 fatty acids was measured, and subjects with the metabotype associated with relatively more omega-3 (DHA) production had lower risk for ACS, OR 0.3 (0.1, 0.5). After adjustment, a third difference emerged for FADS1, where efficient conversion of dgLA to AA was more prevalent among cases than controls. The different proportions of metabotypes in cases and controls allow for calculation of odds ratios. Since single component populations allows for only a continuously increasing or decreasing odds ratio across sample values, a particular advantage of conceptualizing multiple components is the possibility of identify more biologically intuitive odds patterns. Figure 3 plots the estimated odds from the two-component mixture model of D9D activity when expressed as the OA/SA ratio and the odds ratio is frequency of the cases and controls at each activity, the observed odds, and the odds obtained from a means model. As can be observed in the figure, the 2-component mixture model appears to fit the observed data better than the means model, confirming our intuition.
Discussion
Identifying disease risk factors and predicting risk have become key elements in modern health care and effective intervention policy. The prevalent approach to risk identification is through means testing of measured metabolic and lifestyle factors between populations of cases and controls. However, an inherent weakness to means testing is the assumption that collected samples represent a selection from a single population, and the impact of this assumption is most apparent with large heterogeneous sample sets. We demonstrate a test that robustly detects populations with multiple components (aka, multi-modal distributions). Using the test, our study population was empirically found to be multi-modal and thus violates this assumption. Both genetic and environmental factors can provide sources of variance responsible for this violation. For instance some gene polymorphisms can result in functional changes, direct or epistatic, that would impart a discontinuous, digital shift in measures of activity. Alternatively, metabolic variance due to environmental factors, including diet and lifestyle, should impart continuous variance. Thus, a unified explanation of environmental factors and Mendelian genetics implies digital shifts overlain on continuous variation, or multi-modal distributions. Based on these facts, we hypothesize that sample sets with multiple metabotype components, as opposed to a single component, should be expected. Here we term these components metabotypes. Metabotypes are commonly conceived in metabolomic terms, representing broad fingerprint-like patterns of metabolites that act as phenotypes and so inform diagnostic or prognostic studies (Dumas 2012) . Here, we apply the concept of a metabolic phenotype more narrowly to specific metabolic activities and overlay the biomarker concept with the prevailing genetic theory. While studies have merged genetic and metabolic data for risk assessment (Shin et al. 2014 ), here we incorporate prior knowledge of diet-gene interaction to develop a likelihood ratio test that more faithfully reflects the biology of both.
Using simulated sample sets, the LRT test was found to not only detect mixed populations, but in doing so provided great power to discriminate true means in nearly every scenario tested. In addition, the LRT est gives added biological insight. By accounting for the expected variance conferred by functional genetic differences (as the component means themselves), from that conferred by nutritional status and lifestyle (as the variance off means), we give insight into how these axes of risk interact. For instance, because a lifestyle confers risk by elevating a biomarker, it is not necessary that genes which elevate the same biomarker would also confer risk. In cases where genetic risk operates in the opposite direction as nutritional/lifestyle the traditional analyses would obfuscate biomarker interpretation, but would be revealed by the LRT est analysis. The LRT est also effectively identifies important functional phenotypes in lieu of null variants, and so could be used to effectively identify the subset of genes whose polymorphism actually results in functional alterations. Since SNP analyses do not measure functional alterations, this approach could provide guidance to such approaches. Here, we have identified distinct fatty acid metabolism metabotypes which are associated with increased risk of ACS. By implication, we have also identified optimal activities (Fig. 3) , in contrast to means testing techniques which do not allow for local optima as they can only provide monotonic changes. Metabotypes with greater desaturation activity on stearic acid were at increased risk for ACS compared to activity on palmitic acid, and effect that persists after adjusting for other correlated activities. At least two genes encode enzymes with D9D activity in humans (Flowers & Ntambi 2008) , and increasing activity is associated with increase adiposity (Jeyakumar et al. 2009 ). Prior tracer work confirms higher desaturase activity on SA (Rhee et al. 1997) , and this biomarker is a predictor of risk for cardiovascular disease mortality (Warensjo et al. 2008) . By contrast there is no direct evidence for a role of ELOVL6 in heart disease, however by elongating the SCD precursor PA to SA, high ELOVL6 activity is thought to contribute to palmitate-induced lipotoxicity (Green & Olson 2011) . ELVOL6 are related to co-morbidities of heart disease including gene polymorphisms in insulin resistance (Liu et al. 2013b; Morcillo et al. 2011 ) and increased activity in hepatic steatosis (Matsuzaka et al. 2012) . We observed that metabotypes with increased ELOVL6 activity is protective. However, since our analysis focuses on the effect of belonging to a metabotype, and not deviating from a metabotype mean, it is not necessary to conclude these observations are conflicting.
We did not find evidence for FADS2 activity in risk, however efficient metabotypes of ELOVL5 and FADS1 were associated with increased risk, the latter only after adjustment. ELOVL5 polymorphisms were not associated with either risk for myocardial infarction but were associated with risk intermediates such as LDL-cholesterol (Aslibekyan et al. 2012) . Such failure to replicate highlights the potential for methodologies that combine approaches to increase analytical power. The delta5-desaturase activity mediates the conversion of DGLA (20:3n6) to AA (20:4n6) as well as eicosatetraenoic acid (20:4n3) to EPA (20:5n3) and has been associated with numerous pathologies. Based on biomarkers from cholesteryl ester pools, Lu et al. observed a polymorphism of high delta 5-desaturase activity (rs174547) is associated with reduced risk for coronary heart disease (Lu et al. 2012) , and other cases are reported where high d5-desaturase activity is associated with reduced risk (Wang et al. 2003) . Such findings identify activities associated with risk, however our model suggests at least part of the risk results from metabotypes with differing efficiencies, providing insight into possible gene/ lifestyle interaction.
We have approached our analysis based on the assumption that metabotypes result from genetic polymorphisms however other factors, environmental or unknown, could also establish them. In the latter case, environment is common and correlation of metabotypes is more likely, however in the former case, dependence is unnecessary and less likely. Thus, demonstrating independence is an inference (albeit weak) supporting a genetic basis. We make two findings of independence: lack of correlation between fatty acids of different pathways and an additive effect of metabotype membership. Notably, the strongest correlation is observed among closely related activities (outlined in bold), less strong as activities become more distant. Further metabotype information alone, independent of variance off the means predicts a large portion of cases, consistent with independence and direct a role for metabotypes in ACS risk (Supplemental Fig. 2 ).
This approach is complimentary to genomic approaches. We have also reported a GWAS analysis of fatty acid levels from the Framingham Offspring cohort (Tintle et al. 2014) . We found overlap with our results here, including FADS1 and FADS2, but each approach also identified unique activities. The GWAS identified activities not directly in the fatty acid synthesis pathway (e.g. PCOLCE2), however the LRT also found novel results (e.g. delta-9 desaturase and ELOVL5); both approaches have value in the search for metabolic deficiencies associated with risk. One advantage of the LRT is its ability to attribute sampleset components to metabotypes without regard to underlying genomic contributions-SNP analyses are limited to the actual polymorphisms they measure. In the case where multiple SNPs confer the same functional deficit, as would be expected in a case where similar mutations equivalently disrupt allosteric activation or substrate specificity, the LRT approach would fully describe the group differences; further, the LRT would associate them directly with function. Equally attributing all SNPs to levels would be much more difficult.
Implications
Recent reports have highlighted the difficulties associated with residual risk, including one report from this same study where SNP analyses showed no genome-wide associations with myocardial infarction (Morgan et al. 2007 ). Our test not only provides greater explanation of the data, it is formed by combining basic principles of genetics and environmental factors and so provides straightforward interpretation. Since it predicts populations with multi-modal properties, it has the added benefit of not being constrained to the unrealistic prediction that risk is monotonic with respect to activity: risk can either plateau or reach local maxima and minima. While the latter usually requires at least three components (not found here), we identified plateaued risk (Fig. 3) where decreasing D9D activity did not monotonically decrease risk. Identifying such locales could guide interventions by providing metabolically ideal targets, or in the example case, a threshold above which measures to decrease activity could be beneficial.
Limitations
We have interpreted most of our results by extrapolating to the expected genetics underlying the metabotypes; however, factors other than genetics may be responsible for their presence. We have additionally inferred that the biomarkers reflect the apparent functional enzyme activities. While common, this presupposes that changes in precursor rate of appearance and product rate of clearance are not responsible for the changes. Thus, while we have robustly detected metabotypes, we cannot make strong inferences to mechanism. It is hoped we can validate their application to risk estimation in future studies. The discrimination shown here is a demonstration of potential. We have already demonstrated the value in discrimination (Shearer et al. 2009 ); use of the proposed LRT should be done in the context of other best practices in the statistical analysis of metabolomics data (Broadhurst & Kell 2006; Westerhuis et al. 2008; Xia et al. 2013 ). Our method is only likely to detect metabotypes that are widely separated and would be restricted to large datasets. If metabotypes are truly attributable to genetic polymorphisms, the additive genetic model would predict three distinct metabotypes, however in most cases we detect only two. This is likely due to the expected small abundance of recessive metabotypes, and would need to be confirmed in datasets where the recessive phenotype is more abundant.
Conclusions
We have verified a novel approach to understand how fatty acids and other continuous metabolomic datasets could be evaluated for relationships to risk. We further validated this test, in the context of real biological data, to discover risks associated with unique metabotypes and improved biological interpretability, thereby demonstrating the usefulness of approaches that integrate both metabolomic and genomic concepts.
